ArticleHaematologica2020
The molecular basis for the prothrombotic state in sickle cell disease.
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07009821 (SCREENING EmoCamp_ Analysis of Major Haemoglobinopathies Among Newborns in the Campania Region), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SCREENING EmoCamp_ Analysis of Major Haemoglobinopathies Among Newborns in the Campania Region
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- The role of hemoglobin F in sickle cell disease complications: a descriptive secondary analysis.Blood vessels, thrombosis & hemostasis · 2026Article
- Computational Modeling of Pro-inflammatory Cytokine-Enhanced Blood Coagulation.Computational and structural biotechnology journal · 2026Article
- When sickle cell trait is not just trait: risk of VTE.Hematology. American Society of Hematology. Education Program · 2025Review
- Dengue fever uncovers a late diagnosis of sickle cell disease- a case report.BMC infectious diseases · 2025Article
- Abnormalities of hemostasis in sickle cell patients and predisposition to thrombotic risk: a systematic review and meta-analysis.Thrombosis journal · 2025Review
- Association of cell adhesion molecules levels & single nucleotide polymorphisms with vaso-occlusive crisis in sickle cell disease: A cross sectional study.The Indian journal of medical research · 2025Article
- Thrombosis risk in sickle cell disease with HIV co-infection: unraveling the complex interactions and clinical implications - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Key role of long-duration cardiac rhythm monitoring in patients with sickle cell disease with atrial hyperexcitability.Blood advances · 2025Article
- Let's Not Keep Acute Chest Syndrome Under an Umbrella.American journal of respiratory and critical care medicine · 2025Article
- Article
- Risk scores for choledocholithiasis perform poorly in patients with hemolytic diseases: a PEDI database report.Frontiers in pediatrics · 2025Article
- Increased Adhesiveness of Blood Cells Induced by Mercury Chloride: Protective Effect of Hydroxytyrosol.Antioxidants (Basel, Switzerland) · 2024Article
- Atrial arrhythmia in adults with sickle cell anemia: a missing link toward understanding and preventing strokes.Blood advances · 2024Article
- Pulmonary Hypertension in Sickle Cell Disease: Novel Findings of Gene Polymorphisms Related to Pathophysiology.International journal of molecular sciences · 2024Review
- Diagnosis and management of chronic thromboembolic pulmonary hypertension (CTEPH) in sickle cell disease: A review.Pulmonary circulation · 2024Article
- Constitutive hypercoagulability in pediatric sickle cell disease patients with hemoglobin SS genotype.Research and practice in thrombosis and haemostasis · 2024Article
- Editorial: Inflammation, the link between venous and arterial thrombosis.Frontiers in cardiovascular medicine · 2024Article
- VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.Blood advances · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genetic and molecular basis of sickle cell disease (SCD) has long since been characterized but the pathophysiological basis is not entirely defined. How a red cell hemolytic disorder initiates inflammation, endothelial dysfunction, coagulation activation and eventually leads to vascular thrombosis, is yet to be elucidated. Recent evidence has demonstrated a high frequency of unprovoked/recurrent venous thromboembolism (VTE) in SCD, with an increased risk of mortality among patients with a history of VTE. Here, we thoroughly review the molecular basis for the prothrombotic state in SCD, specifically highlighting emerging evidence for activation of overlapping inflammation and coagulation pathways, that predispose to venous thromboembolism. We share perspectives in managing venous thrombosis in SCD, highlighting innovative therapies with the potential to influence the clinical course of disease and reduce thrombotic risk, while maintaining an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.